Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Gerber, D.E, Socinski, M.A, Neal, J.W, Wakelee, H.A, Shirai, K, Sequist, L.V, Rosovsky, R, Lilenbaum, R, Bastos, B.R, Huang, C, Johnson, M.L, Hasketh, P.J, Subramaniam, D.S, Chai, F, Kazakin, J, Schwartz, B.E, Schiller, J.H, Brahmer, J.R
Published in International journal of radiation oncology, biology, physics (01.11.2014)
Published in International journal of radiation oncology, biology, physics (01.11.2014)
Get full text
Journal Article
Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): Metastatic Non-Small Cell Lung Cancer
Gerber, D.E., Socinski, M.A., Neal, J.W., Wakelee, H.A., Shirai, K., Sequist, L.V., Rosovsky, R., Lilenbaum, R., Bastos, B.R., Huang, C., Johnson, M.L., Hasketh, P.J., Subramaniam, D.S., Chai, F., Kazakin, J., Schwartz, B.E., Schiller, J.H., Brahmer, J.R.
Published in International journal of radiation oncology, biology, physics (15.11.2014)
Published in International journal of radiation oncology, biology, physics (15.11.2014)
Get full text
Journal Article